| abstract |
Combination preparations which contain cyclosporin A and a xanthine derivative or FK506 and a xanthine derivative or rapamycin and a xanthine derivative are suitable for use in organ transplantation, cancer, viral diseases or in autoimmune disorders such as systemic lupus erythematosus, rheumatoid arthritis, psoriasis, pemphigus, atopic dermatitis, myositis, multiple sclerosis, nephrotic syndrome (in particular glomerulonephritis), ulcerative colitis or juvenile diabetes. |